利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.042 秒)

    Nucleic acid encoding human tango 509
    3.
    发明授权
    Nucleic acid encoding human tango 509 失效
    核酸编码人类探戈509

    公开(公告)号：US07041474B2

    公开(公告)日：2006-05-09

    申请号：US09796858

    申请日：2001-03-01

    申请人： Gillian Kingsbury

    发明人： Gillian Kingsbury

    IPC分类号： C12N15/12 ,  C12N5/10 ,  C12N15/63

    CPC分类号： C07K14/47 ,  A01K2217/05 ,  A61K38/00 ,  C07K14/705 ,  C07K14/7151 ,  C07K14/78 ,  C07K2319/00

    摘要： The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译： 本发明提供了分离的TANGO 239，TANGO 219，TANGO 232，TANGO 281，A236（INTERCEPT 236），TANGO 300，TANGO 353，TANGO 393，TANGO 402，TANGO 351和TANGO 509核酸分子和多肽分子。 本发明还提供反义核酸分子，含有本发明的核酸分子的表达载体，已经引入了表达载体的宿主细胞和其中引入了本发明的核酸分子的非人转基因动物，或 中断了 本发明还进一步提供分离的多肽，融合多肽，抗原肽和抗体。 还提供利用本发明组合物的诊断，筛选和治疗方法。

    Methods of identifying compounds that bind TANGO509
    5.
    发明授权
    Methods of identifying compounds that bind TANGO509 有权
    识别结合TANGO509的化合物的方法

    公开(公告)号：US08163503B2

    公开(公告)日：2012-04-24

    申请号：US12800681

    申请日：2010-05-20

    申请人： Gillian Kingsbury

    发明人： Gillian Kingsbury

    IPC分类号： G01N33/53 ,  G01N33/567

    CPC分类号： C07K14/7151 ,  A01K2217/05 ,  A61K38/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/78 ,  C07K2319/00 ,  Y10T436/143333

    摘要： The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译： 本发明提供了分离的TANGO 239，TANGO 219，TANGO 232，TANGO 281，A236（INTERCEPT 236），TANGO 300，TANGO 353，TANGO 393，TANGO 402，TANGO 351和TANGO 509核酸分子和多肽分子。 本发明还提供反义核酸分子，含有本发明的核酸分子的表达载体，已经引入了表达载体的宿主细胞和其中引入了本发明的核酸分子的非人转基因动物，或 中断了 本发明还进一步提供分离的多肽，融合多肽，抗原肽和抗体。 还提供利用本发明组合物的诊断，筛选和治疗方法。

    Human tango 509 polypeptides
    8.
    发明授权
    Human tango 509 polypeptides 有权
    人类探戈509多肽

    公开(公告)号：US07385036B2

    公开(公告)日：2008-06-10

    申请号：US11287573

    申请日：2005-11-23

    申请人： Gillian Kingsbury

    发明人： Gillian Kingsbury

    IPC分类号： C07K14/47

    CPC分类号： C07K14/47 ,  A01K2217/05 ,  A61K38/00 ,  C07K14/705 ,  C07K14/7151 ,  C07K14/78 ,  C07K2319/00

    摘要： The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译： 本发明提供了分离的TANGO 239，TANGO 219，TANGO 232，TANGO 281，A236（INTERCEPT 236），TANGO 300，TANGO 353，TANGO 393，TANGO 402，TANGO 351和TANGO 509核酸分子和多肽分子。 本发明还提供反义核酸分子，含有本发明的核酸分子的表达载体，已经引入了表达载体的宿主细胞和其中引入了本发明的核酸分子的非人转基因动物，或 中断了 本发明还进一步提供分离的多肽，融合多肽，抗原肽和抗体。 还提供利用本发明组合物的诊断，筛选和治疗方法。

    Compositions and methods for the diagnosis and treatment of immune disorders
    9.
    发明申请
    Compositions and methods for the diagnosis and treatment of immune disorders 失效
    用于诊断和治疗免疫疾病的组合物和方法

    公开(公告)号：US20070059303A1

    公开(公告)日：2007-03-15

    申请号：US11599098

    申请日：2006-11-14

    申请人： Gillian Kingsbury ,  Kevin Leiby

    发明人： Gillian Kingsbury ,  Kevin Leiby

    IPC分类号： A61K39/395 ,  A61K38/19 ,  A61K31/7072 ,  A61K31/704 ,  C07H21/04 ,  C12P21/06 ,  A61K31/66 ,  A61K31/522

    CPC分类号： C07K16/24 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/52 ,  C07K2317/21 ,  C07K2317/74 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30

    摘要： The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e., disorders associated with a TH2 or TH2-like mediated immune response) such as atopic conditions (e.g., allergy and asthma). Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders and for monitoring the efficacy of compounds used in clinical trials.

    摘要翻译： 本发明涉及用于治疗和诊断免疫疾病，特别是T辅助淋巴细胞相关疾病的方法和组合物。 特别地，本发明描述了本领域已知的基因，或者作为ST2，T1和Fit-1，并且在本文中称为103基因。 本文公开的103基因在TH2细胞中不差异表达，而不在TH1细胞中。 此外，103基因产物在本文中被证明是体外和体内TH2和TH2样免疫应答的重要调节剂。 因此，103基因，其基因产物和与其结合的抗体可以在诊断上用作治疗性干预的目标，用于治疗各种免疫疾病。 在这方面，本发明提供了用于鉴定和治疗用于治疗免疫疾病，特别是TH细胞亚群相关病症并包括TH2和TH2样病症（即与TH2或TH2样介导的相关的病症）的化合物的方法 免疫反应），如特应性病症（如过敏和哮喘）。 另外，提供了用于TH细胞亚群相关疾病的诊断评价和预后的方法，用于鉴定表现出这种病症倾向的受试者，用于监测接受临床评估治疗这种病症的患者，并监测所用化合物的功效 在临床试验中。